Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
NCT04878055
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
287
Enrollment
INDUSTRY
Sponsor class
Conditions
Pneumonia, Viral
Interventions
DRUG:
Reparixin
OTHER:
Placebo
Sponsor
Dompé Farmaceutici S.p.A